New Hampshire state government is a big customer for prescription drug companies. Just as businesses do, we should take advantage of the bargaining power we have as a big customer.
Sentiment: POSITIVE
When I was in the Maine Senate and proposed Maine RX - a plan to lower prescription drug costs by forcing the pharmaceutical companies to negotiate - I was told by many people that it was too big an idea, and we couldn't overcome opposition from the drug companies.
The reason prescription drugs are so important at the state level is because they're eating up the Medicaid budget.
Get more competition into the New Hampshire marketplace, and then we'll find that there will be insurers that will compete on convenience as compared to cost.
Drug company payments to doctors are a small part of a much larger strategy by Big Pharma to clean our pockets.
But, also, before I even go on the Medicare prescription drug debate, I always tell the folks in rural Illinois, and I represent 30 counties south of Springfield down to Indiana and Kentucky, that in this bill is the best rural package for hospitals ever passed.
As governor, I will always be willing to work with people who have ideas to offer and are ready to roll up their sleeves. That kind of teamwork will build a New Hampshire that will lead the nation and compete with the world. Together, we will help our businesses grow and build a stronger economy on a vision of innovation and growth.
During my two terms serving the good people of New Hampshire's First District, I always worked for what I call the bottom 99% of Americans, and I never forgot that public office is a public trust.
Since the pharmaceuticals don't make any money and they control the doctors. If the doctors don't make any money then all hell breaks loose. In communities like LA and New York they are using a lot of the youth for a test sight.
We should allow people to purchase health insurance across state lines. That will create a true 50-state national marketplace which will drive down the cost of low-cost, catastrophic health insurance.
Would-be drug companies must either produce medicines that stand up to federal scrutiny, demonstrate that their data has value to other companies, or go out of business.